Chris Shibutani
Stock Analyst at Goldman Sachs
(2.22)
# 776
Out of 4,829 analysts
99
Total ratings
66.67%
Success rate
2.18%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $31.59 | +216.56% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $1.39 | +115.83% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $7.88 | +90.48% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $31.27 | +2.33% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $97.27 | +40.85% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $10.99 | +200.27% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $310.80 | -2.83% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $33.36 | +52.90% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $154.14 | +0.56% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $4.60 | -13.04% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $8.71 | +129.62% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $755.57 | -4.31% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $24.17 | +7.57% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $120.43 | +27.04% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $190.07 | -8.98% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.71 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $48.18 | +43.21% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $18.61 | -30.15% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $41.88 | -45.08% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $1.21 | +4,032.23% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $32.17 | +61.64% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $23.09 | +159.85% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $8.82 | +104.08% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.31 | +1,197.71% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.36 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.53 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.04 | - | 4 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $29.38 | - | 3 | May 2, 2017 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $31.59
Upside: +216.56%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $1.39
Upside: +115.83%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $7.88
Upside: +90.48%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $31.27
Upside: +2.33%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $97.27
Upside: +40.85%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $10.99
Upside: +200.27%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $310.80
Upside: -2.83%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $33.36
Upside: +52.90%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $154.14
Upside: +0.56%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $4.60
Upside: -13.04%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $8.71
Upside: +129.62%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $755.57
Upside: -4.31%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $24.17
Upside: +7.57%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $120.43
Upside: +27.04%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $190.07
Upside: -8.98%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.71
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $48.18
Upside: +43.21%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $18.61
Upside: -30.15%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $41.88
Upside: -45.08%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $1.21
Upside: +4,032.23%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $32.17
Upside: +61.64%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $23.09
Upside: +159.85%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $8.82
Upside: +104.08%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $1.31
Upside: +1,197.71%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.36
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.53
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $3.04
Upside: -
May 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $29.38
Upside: -